Pneumococcal Polysaccharide Vaccination (PPV23) Vaccination and Risk of Cardiovascular Events
- Random-effects Bayesian and frequentist meta-analyses
- systematic search of MEDLINE, Embase, and Cochrane CENTRAL
- randomized controlled trials and propensity-adjusted observational cohort studies
+2 more
- systematic search of MEDLINE, Embase, and Cochrane CENTRAL
- randomized controlled trials and propensity-adjusted observational cohort studies
Authors' conclusion
Current evidence remains insufficient to establish a cardiovascular benefit of PPV23. Further adequately powered evidence is needed to resolve the remaining uncertainty.
Study context
- Population
- Studies comparing PPV23 with placebo or no vaccination reporting acute coronary syndrome (ACS) events, stroke, or all-cause mortalitystudies: 2 randomized trials and 4 propensity-adjusted cohort studies · randomized trials 2 · propensity-adjusted cohort studies 4
- Participants
- Six participants
- Comparison
- PPV23 with placebo or no vaccination
Pooled result
As reported in the abstract
ACS events (Bayesian analysis)
posterior probability of any benefit
85%
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Stroke (Bayesian analysis) | 1.10 (0.83–1.48) | |
| All-cause mortality (Bayesian analysis) | 1.02 (0.83–1.29) | |
| 0.512Hazard ratio (log scale) |
Frequentist analyses
- Directionally consistent, with 95% CIs crossing the null for ACS events, stroke, and all-cause mortality
Certainty of evidence (GRADE)
- Low across all outcomes
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
PPV23 Vaccination and Risk of Cardiovascular Events. JACC Adv. Published 17 August 2026. doi:10.1016/j.jacadv.2026.103134
Summarised from the published abstract; every number is checked against it